Kalaris Therapeutics Inc (KLRS)

Currency in USD
4.1500
+0.0300(+0.73%)
Closed·
4.0500-0.1000(-2.41%)
·
KLRS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.99004.3050
52 wk Range
2.500011.8800
Key Statistics
Prev. Close
4.12
Open
4.1
Day's Range
3.99-4.305
52 wk Range
2.5-11.88
Volume
81.24K
Average Volume (3m)
259.3K
1-Year Change
65.3386%
Book Value / Share
2.42
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KLRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.7143
Upside
+350.95%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings upwards for the upcoming period

Kalaris Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.7143
(+350.95% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Buy---New CoverageJun 15, 2026
Wedbush
Buy17.00+309.64%-New CoverageMay 14, 2026
Citizens
Buy25.00+502.41%26.00MaintainMay 13, 2026
Raymond James
Buy23.00+454.22%-MaintainMay 12, 2026
Morgan Stanley
Buy14.00+237.35%-New CoverageApr 16, 2026

Earnings

Latest Release
Aug 11, 2026
EPS / Forecast
-0.48 / -0.50
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

KLRS Income Statement

Compare KLRS to Peers and Sector

Metrics to compare
KLRS
Peers
Sector
Relationship
P/E Ratio
−2.2x−3.7x−0.4x
PEG Ratio
−0.03−0.040.00
Price/Book
1.7x2.1x2.6x
Price / LTM Sales
-73.2x3.1x
Upside (Analyst Target)
381.9%143.9%48.6%
Fair Value Upside
Unlock9.1%5.8%Unlock

Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
625.19K2.63%2.59M
Other Institutional Investors
31.72M97.37%131.62M
Public Companies & Retail Investors
0.000.00%0.00
Total
32.34M100.00%134.22M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Samsara BioCapital LLC54.11%12,881,17553,457
Samsara Biocapital, L.P.44.79%10,661,49944,245

People Also Watch

0.155
GOSS
-1.90%
70.740
AXTI
-3.25%
4.660
AQST
+3.67%
56.50
SRRK
+2.26%
33.255
VTVT
+0.53%

FAQ

What Is the Kalaris Therapeutics (KLRS) Stock Price Today?

The Kalaris Therapeutics stock price today is 4.1500 USD.

What Stock Exchange Does Kalaris Therapeutics Trade On?

Kalaris Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Kalaris Therapeutics?

The stock symbol for Kalaris Therapeutics is "KLRS."

What Is the Kalaris Therapeutics Market Cap?

As of today, Kalaris Therapeutics market cap is 98.7900M USD.

What Is Kalaris Therapeutics's Earnings Per Share (TTM)?

The Kalaris Therapeutics EPS (TTM) is -2.0646.

When Is the Next Kalaris Therapeutics Earnings Date?

Kalaris Therapeutics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is KLRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Kalaris Therapeutics Stock Split?

Kalaris Therapeutics has split 1 times.

How Many Employees Does Kalaris Therapeutics Have?

Kalaris Therapeutics has 20 employees.

What is the current trading status of Kalaris Therapeutics (KLRS)?

As of Aug 24, 2026, Kalaris Therapeutics (KLRS) is trading at a price of 4.1500 USD, with a previous close of 4.1200 USD. The stock has fluctuated within a day range of 3.9900 USD to 4.3050 USD, while its 52-week range spans from 2.5000 USD to 11.8800 USD.

What Is Kalaris Therapeutics (KLRS) Price Target According to Analysts?

The average 12-month price target for Kalaris Therapeutics is 18.7143 USD, with a high estimate of 25 USD and a low estimate of 7 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +350.95% Upside potential.

What Is the KLRS Premarket Price?

KLRS's last pre-market stock price is 3.8500 USD. The pre-market share volume is 110.0000, and the stock has decreased by -0.2700, or -6.5500%.

What Is the KLRS After Hours Price?

KLRS's last after hours stock price is 4.0500 USD, the stock has decreased by -0.1000, or -2.4100%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.